Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells

Summary

Vascular calcification is characterized by cellular transdifferentiation and expression of bone-related matrix proteins that result in the presence of bone-like structures in the vascular wall. Interleukin (IL)-4, a pleiotropic cytokine, and osteoprotegerin (OPG), an essential regulator of osteoclast biology, have both been linked to vascular disease. Here, we assessed the role of IL-4 and OPG in vascular calcification in vitro. IL-4 induced OPG mRNA levels and protein secretion by 5-fold in a dose-and time-dependent fashion in human coronary artery smooth muscle cells (CASMC). Activation of the transcription factor STAT6 preceded IL-4-induced OPG expression, and blockade of IL-4-induced STAT6 activation by the phospholipase C inhibitor D609 decreased OPG expression. Long-term exposure of IL-4 for 4 weeks resulted in transformation of CASMC towards an osteoblastic phenotype, based on the expression of the transcription factor Cbfa1 and increased mineral deposition. Notably, calcification of CASMC was inhibited by gene silencing of Cbfa1. During osteogenic transformation, IL-4 down-regulated OPG production in CASMC. IL-4 has differential effects in CASMC: While short-term exposure enhances OPG production through a STAT6-dependent mechanism, long-term exposure causes Cbfa1-dependent osteogenic transformation anda decreased production of OPG, an inhibitor of bone resorption.

Keywords

Cbfa1 - interleukin-4 - osteoprotegerin - smooth muscle cells - vascular calcification

• References

• 1 Simonet WS, Lacey DL, Dunstan CR. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
• 2 Lacey DL, Timms E, Tan HL. et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
• 3 Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
• 4 Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000; 21: 495-502.
• 5 Bucay N, Sarosi I, Dunstan CR. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
• 6 Min H, Morony S, Sarosi I. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blockinga process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-74.
• 7 Price PA, June HH, Buckley JR. et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-6.
• 8 Dhore CR, Cleutjens JP, Lutgens E. et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003.
• 9 Schoppet M, Al-Fakhri N, Franke FE. et al. Localization of osteoprotegerin (OPG), TNF-related apoptosis-inducing ligand (TRAIL), and receptor activator of NF-kB ligand (RANKL) in Mönckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-12.
• 10 Jono S, Ikari Y, Shioi A. et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4.
• 11 Schoppet M, Sattler AM, Schaefer JR. et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8.
• 12 Kiechl S, Schett G, Wenning G. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-80.
• 13 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-7.
• 14 Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet 2001; 358: 257-9.
• 15 Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999; 340: 115-26.
• 16 Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-70.
• 17 George J, Mulkins M, Shaish A. et al. Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice. Atherosclerosis 2000; 153: 403-11.
• 18 King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor^−/−mice. Arterioscler Thromb Vasc Biol 2002; 22: 456-61.
• 19 George J, Shoenfeld Y, Gilburd B. et al. Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis . Circ Res 2000; 86: 1203-10.
• 20 Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-25.
• 21 Ueno K, Katayama T, Miyamoto T. et al. Interleukin-4 enhances in vitro mineralization in human osteoblast-like cells. Biochem Biophys Res Commun 1992; 189: 1521-6.
• 22 Ishibashi H, Harumiya S, Koshihara Y. Involvement of type VI collagen in interleukin-4-induced mineralization by human osteoblast-like cells in vitro . Biochim Biophys Acta 1999; 1472: 153-64.
• 23 Hofbauer LC, Shui C, Riggs BL. et al. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280: 334-9.
• 24 Zamorano J, Rivas MD. Garcia-Trinidad, et al. Phosphatidylcholine-specific phospholipase C activity is necessary for the activation of STAT6. J Immunol 2003; 171: 4203-9.
• 25 Thomas T, Gori F, Khosla S. et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630-8.
• 26 Viereck V, Siggelkow H, Tauber S. et al. Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 2002; 86: 348-56.
• 27 Viereck V, Grundker C, Friess SC. et al. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J Bone Miner Res 2005; 20: 2036-43.
• 28 Kelly-Welch AE, Hanson EM, Boothby MR. et al. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003; 300: 1527-8.
• 29 Finkelman FD, Shea-Donohue T, Morris SC. et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 2004; 201: 139-55.
• 30 Lubberts E, Joosten LA, Chabaud M. et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105: 1697-710.
• 31 Mangashetti LS, Khapli SM, Wani MR. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kB and Ca²⁺ signaling. J Immunol 2005; 175: 917-25.
• 32 Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest 2001; 107: 1375-85.
• 33 Satterthwaite G, Francis SE, Suvarna K. et al. Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am HeartJ 2005; 150: 488-99.
• 34 Moreno JL, Kaczmarek M, Keegan AD. et al. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. J Immunol 2003; 102: 1078-86.
• 35 Baetta R, Soma M, De-Fraja C. et al. Upregulation and activation of Stat6 precede vascular smooth muscle cell proliferation in carotid artery injury model. Arterioscler Thromb Vasc Biol 2000; 20: 931-9.
• 36 Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-70.
• 37 Doherty TM, Fitzpatrick LA, Inoue D. et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004; 25: 629-72.
• 38 Tyson KL, Reynolds JL, McNair R. et al. Osteo/ chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-94.
• 39 Gori F, Hofbauer LC, Dunstan CR. et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141: 4768-76.
• 40 Otto F, Thornell AP, Crompton T. et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-71.
• 41 Nikolovski J, Kim BS, Mooney DJ. Cyclic strain inhibits switching of smooth muscle cells to an osteoblast-like phenotype. FASEB J 2003; 17: 455-7.
• 42 Steitz SA, Speer MY, Curinga G. et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and down-regulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-54.
• 43 Engelse MA, Neele JM, Bronckers AL. et al. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor α-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res 2001; 52: 281-9.
• 44 Jono S, McKee MD, Murry CE. et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-7.